Status:
UNKNOWN
The Clinical Efficacy of Drug Sensitive Neoadjuvant Chemotherapy Based on Organoid Versus Traditional Neoadjuvant Chemotherapy in Advanced Gastric Cancer
Lead Sponsor:
Shanghai Minimally Invasive Surgery Center
Collaborating Sponsors:
Ruijin Hospital
Shanghai OneTar Biomedicine Co., Ltd.
Conditions:
Advanced Gastric Carcinoma
Eligibility:
All Genders
18-80 years
Brief Summary
Neoadjuvant chemotherapy has become the mainstream recommended treatment for advanced gastric cancer. However, due to the heterogeneity of gastric cancer, part of some patients fail to benefit from th...
Eligibility Criteria
Inclusion
- Age between 18 and 80 years
- A biopsy proven histological diagnosis of gastric adenocarcinoma or high-grade intraepithelial neoplasia
- Tumor located at stomach
- Chest/abdomen/pelvis CT scans or gastric cancer staging CT scan evaluate the clinical stage of tumor as stage III:
- A. preoperative staging cT3-4N1-2 B. excluding distant organ metastasis (M0)
- Eastern Cooperative Oncology Group (ECOG) score ≤1
- Willing to participate and informed consent signed
Exclusion
- Pregnant or lactating women
- Synchronous or heterochronic malignant carcinomas
- History of malignant carcinomas
- Clinical evidence of metastasis
- Abnormal heart, lung, liver, kidney, hematopoietic function and bone marrow reserve function, unable to tolerate surgical treatment and chemotherapy
- Mental illness or other serious cardiovascular disease
- Emergency procedure
Key Trial Info
Start Date :
April 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT05351398
Start Date
April 1 2022
End Date
December 1 2023
Last Update
April 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Ruijin Hospttal
Shanghai, Sahnghai, China, 200000